Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine +/- Sunitinib in Pancreatic Cancer
NCT00673504Phase 2Completed
- Sponsor
- Central European Society for Anticancer Drug Research
- Start
- Apr 2008
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of sunitinib in pancreatic cancer (PC) (2 arms), sponsored by Central European Society for Anticancer Drug Research. Primary endpoint: Time to Progression. Started Apr 2008; status: completed.
02
Drugs
sunitinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00673504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00673504.